Skip to main content

23andMe shares surge 17% in their trading debut after merger with Richard Branson-backed SPAC

Shares of consumer genetics company 23andMe rose about 17% in their trading debut Thursday, after the provider of home DNA test kits went public via a merger with Richard Branson's special-purpose acquisition corporation, or SPAC, VG Acquisition Corp.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.